Skip to main content


Log in

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

  • Published:
Calcified Tissue International Aims and scope Submit manuscript


The effects of 7 years of risedronate treatment were evaluated in a second 2-year extension of a 3-year vertebral fracture study in women with osteoporosis. For the first 5 years of the study, women received risedronate 5 mg/day or placebo according to the original randomization, with maintenance of blinding. All the women who entered into the 6–7 years extension study received risedronate 5 mg/day. Endpoints included vertebral and nonvertebral fracture assessments, changes in biochemical markers of bone turnover, and bone mineral density (BMD) measurements. A total of 164 women (placebo/risedronate group, 81; risedronate group, 83) entered the 6–7 years extension study and 136 (83%) completed the study. Annualized incidence of new vertebral fractures during the 6–7 years was similar between the 2 treatment groups (3.8%). The incidence of vertebral fractures did not change in the 7-year risedronate group during the 6–7 years as compared to 4–5 years, while a significant reduction was observed in the placebo group that switched to risedronate treatment during years 6–7. The incidence of nonvertebral fractures was 7.4% and 6.0% in the placebo/risedronate and risedronate groups, respectively, during years 6–7. Urinary N-telopeptide decreased from baseline by 54% and 63% at 3 months and 7 years, respectively, in the risedronate group. The increases in BMD from baseline after 5 years of risedronate treatment were maintained or increased further during years 6–7; lumbar spine BMD after 5 and 7 years of risedronate treatment increased from baseline by 8.8% and 11.5%, respectively, for this extension study population. Risedronate was well tolerated and the occurrence of upper gastrointestinal adverse events was low. After 7 years of continuous risedronate treatment there were significant increases in BMD and decreases in bone turnover to within premenopausal levels and there was no indication of any loss of anti-fracture efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others


  1. JY Reginster HW Minne OH Sörensen et al. (2000) ArticleTitleRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83–91 Occurrence Handle10.1007/s001980050010 Occurrence Handle1:CAS:528:DC%2BD3cXhvFGgsr0%3D Occurrence Handle10663363

    Article  CAS  PubMed  Google Scholar 

  2. ST Harris NB Watts HK Genant et al. (1999) ArticleTitleEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis JAMA 282 1344–1352 Occurrence Handle10.1001/jama.282.14.1344 Occurrence Handle1:CAS:528:DyaK1MXmvFansr0%3D Occurrence Handle10527181

    Article  CAS  PubMed  Google Scholar 

  3. NB Watts S Adami CH Chesnut (2001) ArticleTitleRisedronate reduces the risk of clinical vertebral fractures in just 6 months (abstract SU409) ASBMR 23rd Annual meeting . 5407

    Google Scholar 

  4. R Lindsay SL Silverman C Cooper et al. (2001) ArticleTitleRisk of new vertebral fracture in the year following a fracture JAMA 285 320–323 Occurrence Handle10.1001/jama.285.3.320 Occurrence Handle1:STN:280:DC%2BD3M7kslamtw%3D%3D Occurrence Handle11176842

    Article  CAS  PubMed  Google Scholar 

  5. R Lindsay RT Burge DM Strauss (2001) ArticleTitleThe expected cost of new fractures in the year following a vertebral fracture J Bone Miner Res 16 IssueID1 S275

    Google Scholar 

  6. OH Sörensen GM Crawford H Mulder et al. (2003) ArticleTitleLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 120–6 Occurrence Handle10.1016/S8756-3282(02)00946-8 Occurrence Handle12633783

    Article  PubMed  Google Scholar 

  7. PD Miller NB Watts AA Licata et al. (1997) ArticleTitleCyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment Am J Med 103 468–476 Occurrence Handle10.1016/S0002-9343(97)00278-7 Occurrence Handle1:CAS:528:DyaK1cXjvFKgug%3D%3D Occurrence Handle9428829

    Article  CAS  PubMed  Google Scholar 

  8. RP Tonino PJ Meunier R Emkey et al. (2000) ArticleTitleSkeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women J Clin Endocrinol Metab 85 3109–3115 Occurrence Handle10.1210/jc.85.9.3109 Occurrence Handle1:CAS:528:DC%2BD3cXmsVKru70%3D Occurrence Handle10999794

    Article  CAS  PubMed  Google Scholar 

  9. HG Bone D Hosking JP Devogelaer JR Tucci InstitutionalAuthorName for The Alendronate Phase III Osteoporosis Treatment Study Group et al. (2004) ArticleTitleTen years’ experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189–1199 Occurrence Handle10.1056/NEJMoa030897 Occurrence Handle1:CAS:528:DC%2BD2cXit12rsLc%3D Occurrence Handle15028823

    Article  CAS  PubMed  Google Scholar 

  10. DM Black SR Cummings DB Karpf et al. (1996) ArticleTitleRandomised trial of effect of alendronate on risk of fractures in women with existing vertebral fractures Lancet 348 1535–1541 Occurrence Handle10.1016/S0140-6736(96)07088-2 Occurrence Handle1:CAS:528:DyaK2sXisFCktQ%3D%3D Occurrence Handle8950879

    Article  CAS  PubMed  Google Scholar 

  11. ST Harris NB Watts RD Jackson HK Genant RD Wasnich P Ross PD Miller AA Licata CH Chesnutt (1993) ArticleTitleFour-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy Am J Med 95 557–567 Occurrence Handle10.1016/0002-9343(93)90350-X Occurrence Handle1:STN:280:ByuD1c3lvFw%3D Occurrence Handle8259772

    Article  CAS  PubMed  Google Scholar 

  12. DL Schneider EL Barrett-Connor (1997) ArticleTitleUrinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density Arch Intern Med 157 1241–1245 Occurrence Handle10.1001/archinte.157.11.1241 Occurrence Handle1:CAS:528:DyaK2sXktlWqu70%3D Occurrence Handle9183236

    Article  CAS  PubMed  Google Scholar 

  13. EL Rittman B Borah TE Dufresne RJ Phipps JP Sacha SM Jorgensen RT Turner (2002) ArticleTitle3-D synchrotron mCT allows unique insight of changes in bone quality JBMR 17 IssueIDS1 415

    Google Scholar 

  14. JA Clowes RA Hannon TS Yap NR Hoyle A Blumsohn R Eastell (2002) ArticleTitleEffect of feeding on bone turnover markers and its impact on biological variability of measurements Bone 30 886–890 Occurrence Handle10.1016/S8756-3282(02)00728-7 Occurrence Handle1:STN:280:DC%2BD38zhtVSgug%3D%3D Occurrence Handle12052458

    Article  CAS  PubMed  Google Scholar 

  15. R Hannon R Eastell (2000) ArticleTitlePreanalytical variability of biochemical markers of bone turnover Osteoporos Int (supp) 6 S30–S44 Occurrence Handle10.1007/s001980070004

    Article  Google Scholar 

Download references


The authors wish to thank Elaine Taylor for her assistance in the writing and editing of the manuscript and Joanna Tench for her assistance in the preparation of the manuscript. This study was sponsored by The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals, Inc, Cincinnati, Ohio, and Aventis Pharmaceuticals, Inc, Bridgewater, New Jersey).

Author information

Authors and Affiliations


Corresponding author

Correspondence to A. A. Chines.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mellström, D.D., Sörensen, O.H., Goemaere, S. et al. Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis. Calcif Tissue Int 75, 462–468 (2004).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: